PORTFOLIO OVERVIEW
30+ years of biotech investing. Listed in Switzerland and Germany.
Portfolio breakdown
POSITIONS
Vertex Pharmaceuticals
10.4%
Argenx SE
8.0%
Regeneron Pharmaceuticals
7.5%
Scholar Rock
6.2%
Gilead Sciences
5.5%
Revolution Medicines
5.2%
Ionis Pharmaceuticals
4.7%
Viridian Therapeutics
4.6%
Krystal Biotech
4.3%
Crinetics Pharmaceuticals
4.2%
Nuvalent
3.8%
Amgen
3.3%
Enliven Therapeutics
3.2%
Immunocore
2.9%
Alnylam Pharmaceuticals
2.7%
Relay Therapeutics
2.7%
Vaxcyte
2.4%
Vera Therapeutics
2.4%
Damora Therapeutics
2.1%
Rivus Pharmaceuticals
1.9%
Tango Therapeutics
1.8%
Edgewise Therapeutics
1.7%
Jade Biosciences
1.7%
Ultragenyx Pharmaceutical
1.7%
Celldex Therapeutics
1.3%
Annexon
1.0%
Disc Medicine
1.0%
Oruka Therapeutics
0.9%
Monte Rosa Therapeutics
0.7%
Atrium Therapeutics
0.1%
Disease area
Orphan Diseases
Inflammation & Immunology
Oncology
Neurological Diseses
Cardiovascular Diseases
market capitalization (in usd)
> 30 bn
5 - 30 bn
1 - 5 bn
500 mn - 1 bn
<500 mn.
Private
Technology
Small Molecule
Biologics
RNA
Gene- and cell therapy
Facts & key figures
Investment Focus
Innovative biotechnology companies developing differentiated therapies
Primarily invested in listed biotechnology companies, with selective private investments
20–35 target participations
5–8 core positions with meaningful portfolio weights
suitability & risk profile
Designed for long-term investors (5+ years) willing to accept equity risk typical of the biotech sector.
Lower Risk
Higher Risk
Risk metrics (3Y)
1.1
Beta (3Y)
26.5%
Volatility (3Y)
13.4%
Tracking Error
0.51
Sharpe Ratio
NBI (Nasday Biotechnology Index) is used as the benchmark and the reference currency is CHF.
general information
Investment manager
Bellevue Asset Management AG
Custodian bank
Bank Julius Bär AG
Launch date
09.11.1993
Fiscal year end
December 31
Management fee
1.10% p.a.
Legal form
Incorporate company
SFDR category
Article 8
Benefits & risks
Access to global biotech growth
Diversified portfolio of profitable and pipeline companies
Experienced investment management
Dividend policy (~5%)
Equity volatility
Biotech sector swings
Currency risks
Discount/premium to NAV
Up to 15% leverage possible